FDA Clearance: What It Really Means for Cardiac AI Investors

Getting an AI-powered medical device through a regulatory body like the U.S. Food and Drug Administration (FDA) is always treated like the finish line. But for the regulatory affairs and clinical evidence teams on the ground, that milestone is the starting gun. A 510(k) clearance, for example, gives a “reasonable assurance” of safety and effectiveness based on a specific data snapshot, under controlled conditions, by showing it’s substantially equivalent to a device that’s already on the market. It doesn’t give a permanent verdict on performance or guarantee the algorithm will work just as well on the diverse, messy patient populations it will meet in the real world.

What a 510(k) Really Means

When a company like HeartFlow gets a 510(k) for its AI, it’s a signal that the FDA agrees the device is as safe and effective as a legally marketed “predicate” device. It’s a pathway designed to get new tech to market without forcing every single product through massive de novo clinical trials, instead focusing on equivalence. The review itself is tough and digs into the submitted performance benchmarks and validation studies. The one thing this process doesn’t test is how the device will perform, day in and day out, in the wild. The review record at the FDA’s Center for Devices and Radiological Health (CDRH) is a static picture of the device’s capability at that moment, built on specific datasets and patient demographics. It answers the review question perfectly but leaves the deployment question wide open.

The Problem with the Real World

The gap between that tidy review file and the messy reality of ongoing validation becomes obvious once AI cardiac tools are deployed across hundreds of hospitals. Unlike a pacemaker or a stent, AI/ML models can suffer from “algorithmic drift.” This is what happens when the data the AI sees in daily practice, from different scanners, sicker patients, new comorbidities, starts to look different from the clean data it was trained on, causing its performance to degrade over time. Explanation of AI algorithmic drift in medical devices A 510(k) clearance, while a huge achievement, doesn’t account for this drift. It sets a baseline, but how the model performs in a new health system with different patient cohorts is a complete unknown. This is where post-market obligations become so important, picking up the slack where the initial clearance leaves off.

Post-Market Surveillance Isn’t Optional

The FDA’s framework already has a mechanism for this: Post-Market Surveillance (PMS). It’s designed to monitor device safety and effectiveness in routine clinical use, and for AI, it’s not just a good idea, it’s the only way to operate responsibly. Good PMS is how you catch algorithmic drift or discover that your model is less accurate for a specific subgroup before it turns into a real safety issue. The CDRH is constantly analyzing real-world evidence (RWE) from adverse event reports, medical device reports (MDRs), and other sources to see how AI systems are doing outside the bubble of their initial studies. FDA guidance on Post-Market Surveillance for medical devices These insights from the field give you the true benefit-risk profile of an AI device. For AI-enabled cardiac tools, the challenge is proving that the original “reasonable assurance” from your clearance holds up for every single patient you encounter. That requires a proactive plan for monitoring, data collection, and sometimes model retraining and re-validation. The Predetermined Change Control Plan (PCCP) is a framework that helps manage this, letting manufacturers define how they’ll make certain modifications to a model as it learns, all without needing to file a brand new submission for every update. It’s a way to adapt and improve while keeping regulators in the loop. FDA discussion paper on Predetermined Change Control Plans

The Shared Burden of Cardiac AI

You can see this playing out with companies like iRhythm Technologies and AliveCor. They’re both in the cardiac AI space, and even after getting their regulatory clearances, their journeys show the constant scrutiny and evidence generation that’s required after launch. For them, just like for HeartFlow, getting clearance is simply the first step in building a long-term, trustworthy evidence base. The work of researchers like Harlan Krumholz, who studies the real-world impact of medical technology, puts a fine point on it, showing the difference between how an AI performs in a trial versus how it affects actual patient outcomes in diverse communities. His work gets right at the gap between pre-market files and post-market reality. So the big question for the entire cardiac AI peer set is this: how do you continuously validate your algorithm to make sure it stays consistent, equitable, and safe for every kind of patient it serves? The clearance process isn’t failing. It’s a snapshot, and real-world deployment is a feature-length film. For those of us on regulatory and clinical evidence teams, our job is to champion a continuous validation mindset. Responsible AI deployment demands ongoing vigilance long after the initial regulatory nod to protect patients and deliver on the technology’s promise.